Shanghai Ovarian Cancer and Family Care Project
ConditionOvarian Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorShanghai First Maternity and Infant Hospital
About this trial
Ovarian cancer is the most lethal gynaecological malignancy, but its incidence in the general population is low. Due to the lack of effective prevention and successful screening approaches, most cases are diagnosed at advanced stages, leading to poor prognosis. In order to address the research requirements pertaining to ovarian cancer, the Shanghai Ovarian Cancer and Family Care Project was established. This initiative offers hospital-based resources for investigating ovarian cancer and high-risk populations. The project comprises an on-going ovarian cancer cohort, a high-risk population cohort, and a healthy population cohort. By leveraging these comprehensive cohorts, the project provides a unique platform for in-depth studies on the detection, prevention, early diagnosis, treatment, and prognosis of ovarian cancer.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients attending the oncology department require differential diagnosis of ovarian cancer.
Patients with known high-risk factors for ovarian cancer, such as history of ovarian cancer or BRCA-associated cancer, etc.
Patients attending the Physical Examination Center who have normal findings on physical examination and no symptoms.
Disqualifiers
Individuals with evidence of another active cancer.
Individuals who have prior bilateral oophorectomy.
Individuals who are unwilling or unable to sign the informed consent form.
Trial population
Patients attending the oncology department; patients with known risk factors for ovarian cancer; healthy individuals who are in good health determined by physical examination.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
3,546 Participants
are grouped into 3 trial groupsGroup A: Ambispective patient cohort
Group B: High-risk population cohort
Group C: Healthy control cohort
Trial outcomes
Primary outcomes
1
Death due to ovarian cancer
Death due to ovarian cancer determined by independent outcomes committee.
Time frame
From diagnosis of ovarian cancer until October 31, 2028.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov